Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of sintilimab, a selective anti-PD-1 monoclonal antibody, and nab-paclitaxel (albumin-bound paclitaxel), a chemotherapy agent. This combination demonstrates synergistic antitumor activity by combining immune checkpoint inhibition with cytotoxic effects. Sintilimab blocks the interaction between PD-1 and its ligands to restore T-cell immune function, while nab-paclitaxel disrupts microtubule dynamics leading to cell cycle arrest and apoptosis. The combination is being investigated for various advanced cancers including cervical cancer, biliary tract cancer, and gastric/gastroesophageal junction cancer.
- Brand names
- Abraxane + sintilimab
- Other names
- nab-paclitaxel + sintilimabprotein-bound paclitaxel + sintilimabpaclitaxel albumin-stabilized nanoparticle formulation + sintilimab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sintilimab + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + nab-paclitaxel.